牛牛AI助理已提取核心訊息
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 2,101,496 shares of Avenue Therapeutics common stock on January 2, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,133,886 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This significant acquisition reflects changes in the ownership stake that Fortress Biotech, Inc. has in Avenue Therapeutics.
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 2,101,496 shares of Avenue Therapeutics common stock on January 2, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,133,886 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This significant acquisition reflects changes in the ownership stake that Fortress Biotech, Inc. has in Avenue Therapeutics.
Fortress Biotech, Inc. 報告稱，2024年1月2日完成了一項交易，涉及收購2,101,496股Avenue Therapeutics普通股。這些股票是免費授予的，交易價格爲0.00美元。在這筆交易之後，豐澤生物科技在Avenue Therapeutics的直接持股量增加到總共3,133,886股。根據交易代碼 “A”，該交易的性質被描述爲贈款、獎勵或其他收購。這項重大收購反映了豐澤生物科技公司在Avenue Therapeutics的所有權的變化。
Fortress Biotech, Inc. 報告稱，2024年1月2日完成了一項交易，涉及收購2,101,496股Avenue Therapeutics普通股。這些股票是免費授予的，交易價格爲0.00美元。在這筆交易之後，豐澤生物科技在Avenue Therapeutics的直接持股量增加到總共3,133,886股。根據交易代碼 “A”，該交易的性質被描述爲贈款、獎勵或其他收購。這項重大收購反映了豐澤生物科技公司在Avenue Therapeutics的所有權的變化。
有用
沒用